APM vs. CTXR, LSB, LGVN, NAII, DRRX, CDIO, ATHE, LVTX, GDTC, and EQ
Should you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include Citius Pharmaceuticals (CTXR), Lakeshore Biopharma (LSB), Longeveron (LGVN), Natural Alternatives International (NAII), DURECT (DRRX), Cardio Diagnostics (CDIO), Alterity Therapeutics (ATHE), LAVA Therapeutics (LVTX), CytoMed Therapeutics (GDTC), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry.
Aptorum Group vs.
Aptorum Group (NASDAQ:APM) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Aptorum Group. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for Aptorum Group. Aptorum Group's average media sentiment score of -0.19 beat Citius Pharmaceuticals' score of -0.50 indicating that Aptorum Group is being referred to more favorably in the media.
3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aptorum Group's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.
Aptorum Group has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.
Citius Pharmaceuticals has a consensus price target of $54.50, suggesting a potential upside of 1,564.12%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Aptorum Group.
Aptorum Group has higher revenue and earnings than Citius Pharmaceuticals.
Citius Pharmaceuticals received 170 more outperform votes than Aptorum Group when rated by MarketBeat users. However, 68.33% of users gave Aptorum Group an outperform vote while only 62.43% of users gave Citius Pharmaceuticals an outperform vote.
Summary
Citius Pharmaceuticals beats Aptorum Group on 8 of the 15 factors compared between the two stocks.
Get Aptorum Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptorum Group Competitors List
Related Companies and Tools
This page (NASDAQ:APM) was last updated on 1/21/2025 by MarketBeat.com Staff
